Events – Clinical Value of Diagnostics https://clinicalvalue.com Tue, 15 Apr 2025 10:37:38 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.2 https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1 Events – Clinical Value of Diagnostics https://clinicalvalue.com 32 32 225041835 APAC Oncology Summit 2024 https://clinicalvalue.com/event/view-the-2024-apac-oncology-summit-webinar-recordings/ Mon, 06 Jan 2025 05:48:44 +0000 https://clinicalvalue.com/?post_type=event&p=9405 Expert talks and panels on genomic profiling, liquid biopsy, and novel gene management in cancer across Asia-Pacific and global contexts....

The post APAC Oncology Summit 2024 appeared first on Clinical Value of Diagnostics.

]]>
Supported by:
 

This content is targeted at healthcare professionals and shall be used as a reference only. This material represents personal viewpoints and is intended to promote the communication and exchange of medical information. This content may contain information otherwise not accessible, approved or valid in your country. Please be aware that we do not take any responsibility for you accessing information which may not comply with any legal process, regulation, registration or usage in the country of your origin. This contentl may contain products or clinical indications that have not yet been registered or approved in your country. Please refer to the locally approved package insert for detailed prescription information or check with your local Roche representative.

Speakers

Dr. Herbert Loong

Deputy Medical Director,
Phase 1 Clinical Trials Centre,
The Chinese University of Hong Kong

Dr. Linda Mileshkin

Director of Medical Oncology,
Peter MacCallum Cancer Centre, Australia

Dr. Sewanti Limaye

Director of Medical & Precision Oncology,
Reliance Foundation Hospital & Research Center, India

Dr. Dejan Juric

Director,
Termeer Center for Targeted Therapies & Investigational Cancer Therapeutics Program,
Massachusetts General Hospital Cancer Centre, U.S.A.

Moderators

 

Dr. Daniel Chan

Senior Consultant,
Medical Oncology,
ICON Cancer Centre, Singapore

Dr. Yoon Sim Yap

Senior Consultant,
Division of Medical Oncology,
National Cancer Centre, Singapore
 

Agenda

Topic

Speakers

Opening and Introduction
Mr. Lance Little
Head of Region Asia Pacific,
Roche Diagnostics Ltd.
Trends and Challenges in Molecular Tumour Board Implementation in Asia-Pacific Region: APAC MTB Expert Consensus Statement
Dr. Herbert Loong
Unlocking the Power of Liquid Biopsy-based Profiling in Clinical Practice
Dr. Linda Mileshkin
Panel Discussion: Facilitating Access to Molecularly Guided Treatment Options by Leveraging Advancements in Genomic Profiling and Molecular Tumour Boards
Panelists:
Dr. Herbert Loong
Dr. Linda Mileshkin
Dr. Aya Helali
Break
All
The Evolution of Comprehensive Genomic Profiling: From Lung Cancer Pioneers to Ovarian and Breast Cancer Paradigms
Dr. Sewanti Limaye
Targeting PIK3CA Mutation in Breast Cancer: From Testing to Therapeutic Strategies
Dr. Dejan Juric
Panel Discussion: Management of Novel Genes in Breast Cancer
Panelists:
Dr. Dejan Juric
Dr. Sewanti Limaye
Dr. Pranav Dorwal
Closing
Dr. Ahmed Elhusseiny
Area Head APAC,
Roche Pharmaceuticals

This material represents personal viewpoint and is intended to promote the communication and exchange of medical information, and shall be used by healthcare professionals as a reference only. This material may contain medicinal products or clinical indications that have not yet been approved in your country. Please refer to the locally approved package insert for detailed prescription information.

The post APAC Oncology Summit 2024 appeared first on Clinical Value of Diagnostics.

]]> 9405 Global Talks Lung Cancer Forum https://clinicalvalue.com/event/global-talks-nsclc-treatment-webinar/ Mon, 22 Jul 2024 01:55:32 +0000 https://clinicalvalue.com/?post_type=event&p=8841 Watch this webinar to get updates on advancements in lung cancer treatment, including resectable NSCLC, thoracic surgery, neoadjuvant immunotherapy....

The post Global Talks Lung Cancer Forum appeared first on Clinical Value of Diagnostics.

]]>

In this webinar, experts in lung cancer from around the globe discuss the latest advancements in lung cancer treatment. Watch the webinar recording to get updates on treatment options for resectable NSCLC, thoracic surgery, and neoadjuvant immunotherapy for NSCLC.

 

You are viewing an International Congress run by Roche and provided to international HCPs from around the world. Please note that prescribing information provided here may vary depending on local approval in each country. For purposes of Global Talk, best efforts were undertaken by Roche to ensure compliance with the applicable law and regulations, however, you should review your local prescribing information and consult directly the local affiliate of the relevant Company to address any questions.

The post Global Talks Lung Cancer Forum appeared first on Clinical Value of Diagnostics.

]]> 8841 Events - NSCLC Treatment Webinar nonadult Empowering Women Through Self-Sampling Towards the Elimination of Cervical Cancer https://clinicalvalue.com/event/empowering-women-through-self-sampling-towards-the-elimination-of-cervical-cancer/ Wed, 26 Jun 2024 12:16:11 +0000 https://clinicalvalue.com/?post_type=event&p=8684 ...

The post Empowering Women Through Self-Sampling Towards the Elimination of Cervical Cancer appeared first on Clinical Value of Diagnostics.

]]> The post Empowering Women Through Self-Sampling Towards the Elimination of Cervical Cancer appeared first on Clinical Value of Diagnostics.

]]> 8684 Future of incorporating HPV self-sampling into Singapore Guideline? Are we ready? https://clinicalvalue.com/event/future-of-incorporating-hpv-self-sampling-into-singapore-guideline-are-we-ready/ Wed, 26 Jun 2024 12:07:07 +0000 https://clinicalvalue.com/?post_type=event&p=8673 ...

The post Future of incorporating HPV self-sampling into Singapore Guideline? Are we ready? appeared first on Clinical Value of Diagnostics.

]]> The post Future of incorporating HPV self-sampling into Singapore Guideline? Are we ready? appeared first on Clinical Value of Diagnostics.

]]> 8673 Overview of the Current Cervical Cancer Screening Landscape in Singapore https://clinicalvalue.com/event/cervical-cancer-screening-singapore/ Wed, 26 Jun 2024 11:46:02 +0000 https://clinicalvalue.com/?post_type=event&p=8643 ...

The post Overview of the Current Cervical Cancer Screening Landscape in Singapore appeared first on Clinical Value of Diagnostics.

]]> The post Overview of the Current Cervical Cancer Screening Landscape in Singapore appeared first on Clinical Value of Diagnostics.

]]> 8643 Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies https://clinicalvalue.com/event/debate-all-resectable-stage-ii-to-iii-nsclc-patients-should-be-treated-with-neoadjuvant-immunotherapies/ Fri, 31 May 2024 03:13:01 +0000 https://clinicalvalue.com/?post_type=event&p=8612 ...

The post Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies appeared first on Clinical Value of Diagnostics.

]]> The post Debate: All resectable stage II to III NSCLC patients should be treated with neoadjuvant immunotherapies appeared first on Clinical Value of Diagnostics.

]]> 8612 Management of early-stage NSCLC with driver mutations https://clinicalvalue.com/event/management-of-early-stage-nsclc-with-driver-mutations/ Fri, 31 May 2024 03:00:32 +0000 https://clinicalvalue.com/?post_type=event&p=8601 ...

The post Management of early-stage NSCLC with driver mutations appeared first on Clinical Value of Diagnostics.

]]> The post Management of early-stage NSCLC with driver mutations appeared first on Clinical Value of Diagnostics.

]]> 8601 21st International Congress of Cytology – HPV Primary Screening with Biomarker Based Triage: A better cervical cancer screening strategy https://clinicalvalue.com/event/21st-international-congress-of-cytology-hpv-primary-screening-with-biomarker-based-triage-a-better-cervical-cancer-screening-strategy/ Tue, 14 May 2024 02:03:05 +0000 https://clinicalvalue.com/?post_type=event&p=8481 ...

The post 21st International Congress of Cytology – HPV Primary Screening with Biomarker Based Triage: A better cervical cancer screening strategy appeared first on Clinical Value of Diagnostics.

]]>

While cervical cancer is preventable, an estimated 14,000 new cases are diagnosed in the United States every year, leading to almost 4,300 deaths from the disease.

In this recording from the 21st International Congress of Cytology (ICC), Prof Mark Stoler shows evidence that the use of HPV DNA tests as the primary form of screening, followed by using p16/Ki-67 dual staining in triage can prove effective in identifying women who are at the highest risk of cervical cancer. This testing method gives actionable results that allows clinicians and health systems to prioritise resources for those who are in need of them.

Watch the recording

The post 21st International Congress of Cytology – HPV Primary Screening with Biomarker Based Triage: A better cervical cancer screening strategy appeared first on Clinical Value of Diagnostics.

]]> 8481 IPVC 2023 – How Peru broke down barriers to cervical cancer screening https://clinicalvalue.com/event/ipvc-2023-how-peru-broke-down-barriers-to-cervical-cancer-screening/ Tue, 14 May 2024 01:58:47 +0000 https://clinicalvalue.com/?post_type=event&p=8476 ...

The post IPVC 2023 – How Peru broke down barriers to cervical cancer screening appeared first on Clinical Value of Diagnostics.

]]>

The World Health Organisation recommends HPV self-sampling to ease emotional and psychological barriers that prevent many women from pursuing screening, thus empowering women to choose the approach that works best for them. Following WHO’s recommendations, Dr Gino Venegas, while serving as Director of Cancer at the Ministry of Health in 2017, developed the National Cervical Cancer plan and implemented a HPV primary screening program. To help achieve a target of 70% screening coverage, Peru dedicated substantial resources to public education and setting up HPV testing facilities in primary care settings in both urban and rural areas.

In this recording from IPVC 2023, Dr Gino Venegas shares how Peru tackled cervical cancer by addressing numerous barriers to screening, such as lack of awareness, affordability challenges, and social stigma around HPV testing.

Watch the recording

The post IPVC 2023 – How Peru broke down barriers to cervical cancer screening appeared first on Clinical Value of Diagnostics.

]]> 8476 IPVC 2023 – Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best https://clinicalvalue.com/event/ipvc-2023-optimising-screening-and-triage-for-cervical-cancer-prof-mark-stoler-on-why-biomarkers-are-best/ Tue, 14 May 2024 01:52:21 +0000 https://clinicalvalue.com/?post_type=event&p=8468 ...

The post IPVC 2023 – Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best appeared first on Clinical Value of Diagnostics.

]]>

p16 and Ki-67 are two biomarkers that indicate the presence of transforming HPV infections. The use of p16/Ki-67 dual staining in the triage of HPV positive results leads to better disease detection, allocation of limited healthcare resources, and peace of mind for the patient. Simultaneously detecting p16 and Ki-67 can also help clinicians recommend follow-up for women who will benefit most from colposcopy, resulting in more disease detection without increasing the colposcopy rate.

In this recording from IPVC 2023, Prof Mark Stoler of the University of Virginia Health System discusses the key benefit of simultaneously detecting p16 and Ki-67 in HPV screening. Watch the recording to find out more.
Watch the recording

The post IPVC 2023 – Optimising screening and triage for cervical cancer: Prof Mark Stoler on why biomarkers are best appeared first on Clinical Value of Diagnostics.

]]> 8468